266 related articles for article (PubMed ID: 35215916)
41. Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison - Texas, July-August 2021.
Hagan LM; McCormick DW; Lee C; Sleweon S; Nicolae L; Dixon T; Banta R; Ogle I; Young C; Dusseau C; Salmonson S; Ogden C; Godwin E; Ballom T; Ross T; Browne H; Harcourt JL; Tamin A; Thornburg NJ; Kirking HL; Salvatore PP; Tate JE
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1349-1354. PubMed ID: 34555009
[TBL] [Abstract][Full Text] [Related]
42. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
Levine-Tiefenbrun M; Yelin I; Katz R; Herzel E; Golan Z; Schreiber L; Wolf T; Nadler V; Ben-Tov A; Kuint J; Gazit S; Patalon T; Chodick G; Kishony R
Nat Med; 2021 May; 27(5):790-792. PubMed ID: 33782619
[TBL] [Abstract][Full Text] [Related]
43. Impact of SARS-CoV-2 Delta and Omicron variants on viral burden and cycle threshold in BNT162b2-vaccinated 12-18 years group.
Ergoren MC; Komurcu K; Tuncel G; Akan G; Ozverel CS; Dalkan C; Kalayci M; Sanlıdag T
Braz J Microbiol; 2022 Dec; 53(4):1937-1940. PubMed ID: 36050578
[TBL] [Abstract][Full Text] [Related]
44. Omicron Variant Generates a Higher and More Sustained Viral Load in Nasopharynx and Saliva Than the Delta Variant of SARS-CoV-2.
Granerud BK; Ueland T; Lind A; Søraas A; Fevang B; Steffensen AK; Al-Baldawi H; Lund-Johansen F; Aukrust P; Halvorsen B; Dahl TB; Dudman S; Müller F; Holter JC
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366518
[TBL] [Abstract][Full Text] [Related]
45. Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults.
Costa R; Bueno F; Albert E; Torres I; Carbonell-Sahuquillo S; Barrés-Fernández A; Sánchez D; Padrón C; Colomina J; Lázaro Carreño MI; Bretón-Martínez JR; Martínez-Costa C; Navarro D
Clin Microbiol Infect; 2021 Dec; 27(12):1858.e1-1858.e7. PubMed ID: 34384874
[TBL] [Abstract][Full Text] [Related]
46. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
47. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
48. RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status.
Costa R; Olea B; Bracho MA; Albert E; de Michelena P; Martínez-Costa C; González-Candelas F; Navarro D
J Infect; 2022 Apr; 84(4):579-613. PubMed ID: 34953901
[No Abstract] [Full Text] [Related]
49. Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections.
Siedner MJ; Boucau J; Gilbert RF; Uddin R; Luu J; Haneuse S; Vyas T; Reynolds Z; Iyer S; Chamberlin GC; Goldstein RH; North CM; Sacks CA; Regan J; Flynn JP; Choudhary MC; Vyas JM; Barczak AK; Lemieux JE; Li JZ
JCI Insight; 2022 Jan; 7(2):. PubMed ID: 34871181
[TBL] [Abstract][Full Text] [Related]
50. Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil.
Estofolete CF; Banho CA; Campos GRF; Marques BC; Sacchetto L; Ullmann LS; Possebon FS; Machado LF; Syrio JD; Araújo Junior JP; Bittar C; Rahal P; Lobo SMA; Ferreira HL; Vasilakis N; Nogueira ML
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206727
[TBL] [Abstract][Full Text] [Related]
51. Quantitative detection of SARS-CoV-2 RNA in nasopharyngeal samples from infected patients with mild disease.
Bustos P; Tambley C; Acevedo A; Andrade W; Leal G; Vidal D; Roldán F; Fasce R; Ramírez E
J Med Virol; 2021 Apr; 93(4):2439-2445. PubMed ID: 33368332
[TBL] [Abstract][Full Text] [Related]
52. Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System - California, March-July 2021.
Malden DE; Bruxvoort KJ; Tseng HF; Ackerson B; Choi SK; Florea A; Tubert J; Takhar H; Aragones M; Hong V; Talarico CA; McLaughlin JM; Qian L; Tartof SY
MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(40):1415-1419. PubMed ID: 34618801
[TBL] [Abstract][Full Text] [Related]
53. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
54. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021.
Taylor CA; Patel K; Pham H; Whitaker M; Anglin O; Kambhampati AK; Milucky J; Chai SJ; Kirley PD; Alden NB; Armistead I; Meek J; Yousey-Hindes K; Anderson EJ; Openo KP; Teno K; Weigel A; Monroe ML; Ryan PA; Henderson J; Nunez VT; Bye E; Lynfield R; Poblete M; Smelser C; Barney GR; Spina NL; Bennett NM; Popham K; Billing LM; Shiltz E; Abdullah N; Sutton M; Schaffner W; Talbot HK; Ortega J; Price A; Garg S; Havers FP;
MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(43):1513-1519. PubMed ID: 34710076
[TBL] [Abstract][Full Text] [Related]
55. SARS-CoV-2 respiratory viral loads and association with clinical and biological features.
Biguenet A; Bouiller K; Marty-Quinternet S; Brunel AS; Chirouze C; Lepiller Q
J Med Virol; 2021 Mar; 93(3):1761-1765. PubMed ID: 32889755
[TBL] [Abstract][Full Text] [Related]
56. Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals.
Caserta LC; Martins M; Cronk B; Anderson R; Eldridge H; Gallow D; Kruppa F; Plocharczyk E; Diel DG
Microbiol Spectr; 2022 Oct; 10(5):e0056322. PubMed ID: 36165775
[TBL] [Abstract][Full Text] [Related]
57. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
[TBL] [Abstract][Full Text] [Related]
58. Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants.
Trobajo-Sanmartín C; Martínez-Baz I; Miqueleiz A; Fernández-Huerta M; Burgui C; Casado I; Baigorría F; Navascués A; Castilla J; Ezpeleta C
Microbiol Spectr; 2022 Apr; 10(2):e0000822. PubMed ID: 35412379
[TBL] [Abstract][Full Text] [Related]
59. Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection.
Epaulard O; Abgrall S; Lefebvre M; Faucher JF; Michon J; Frentiu E; Blanchi S; Janssen C; Charbonnier G; Fresse A; Laurent S; Sandjakian L; Casez P; Mahamat A; Beraud G
Clin Microbiol Infect; 2022 Dec; 28(12):1629-1635. PubMed ID: 35779764
[TBL] [Abstract][Full Text] [Related]
60. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
